ReviewThe Biochemical journal1996
CD28: a signalling perspective.
Review in The Biochemical journal, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Frontiers in oncology · 2022Pooled it
- Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.Journal of clinical pharmacology · 2017Trial
- The perioperative management of geriatric patients in transplantation surgery-clinical, immunological, and translational considerations.Frontiers in transplantation · 2025Review
- Review
- Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen ReceptorIranian biomedical journal · 2020Article
- Colorectal Cancer Immunotherapy: Options and Strategies.Frontiers in immunology · 2020Review
- Functions of NKG2D in CD8Cellular & molecular immunology · 2018Review
- p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes.The Journal of clinical investigation · 2013Article
- The first long-lived mutants: discovery of the insulin/IGF-1 pathway for ageing.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2011Review
- Combinatorial signals from CD28 differentially regulate human immunodeficiency virus transcription in T cells.The Journal of biological chemistry · 2010Article
- The NKG2D receptor: immunobiology and clinical implications.Immunologic research · 2008Review
- Polylactosamine on glycoproteins influences basal levels of lymphocyte and macrophage activation.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells.Infection and immunity · 2007Article
- On cell signalling mechanism of Mycobacterium leprae soluble antigen (MLSA) in Jurkat T cells.Molecular and cellular biochemistry · 2006Article
- Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats.Cancer immunology, immunotherapy : CII · 2006Article
- Differential immune modulatory activity of Pseudomonas aeruginosa quorum-sensing signal molecules.Infection and immunity · 2004Article
- Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases.Arthritis research & therapy · 2004Review
- Article
- Docosahexaenoic acid and other fatty acids induce a decrease in pHi in Jurkat T-cells.British journal of pharmacology · 2003Article
- Genetic analysis of CD28 signaling.Immunologic research · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
CD28 and the related molecule cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), together with their natural ligands B7.1 and B7.2, have been implicated in the differential regulation of several immune responses. CD28 provides signals during T cell activation which are required for the production of interleukin 2 and other cytokines and chemokines, and it has also been implicated in the regulation of T cell anergy and programmed T cell death. The biochemical signals provided by CD28 are cyclosporin A-resistant and complement those provided by the T cell antigen receptor to allow full activation of T cells. Multiple signalling cascades which may be independent of, or dependent on, protein tyrosine kinase activation have been demonstrated to be activated by CD28, including activation of phospholipase C, p21ran, phosphoinositide 3-kinase, sphingomyelinase/ceramide and 5-lipoxygenase. The relative contributions of these cascades to overall CD28 signalling are still unknown, but probably depend on the state of activation of the T cell and the level of CD28 activation. The importance of these signalling cascades (in particular the phosphoinositide 3-kinase-mediated cascade) to functional indications of CD28 activation, such as interleukin 2 gene regulation, has been investigated using pharmacological and genetic manipulations. These approaches have demonstrated that CD28-activated signalling cascades regulate several transcription factors involved in interleukin 2 transcriptional activation. This review describes in detail the structure and expression of the CD28 and B7 families, the functional outcomes of CD28 ligation and the signalling events that are thought to mediate these functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.